Canada’s Intellectual Property Firm

Smart & Biggar partners examine biologics and biosimilars in Canada on LSPN Connect

Smart & Biggar partners David Schwartz, from our life science patent practice, and Urszula Wojtyra, from our pharmaceutical litigation practice, will present a webinar update on biologics and biosimilars on Thursday, November 12, 2020 through LSPN Connect.

Sharing with the LSPN Connect member community, Urszula and David will provide an overview of Canada’s regulatory and intellectual property regimes as they apply to biologics and biosimilars.  They will discuss the regulatory pathway for marketing approval, data protection, patent linkage and litigation, and current biosimilar approvals and applications, and provide a comparison to the US and European regimes.

Registration for the webinar, ‘North of the Border: Overview of Biologics and Biosimilars in Canada’, is available here.

LSPN Connect is an exclusive online content and networking platform that connects a global community of life sciences professionals and IP experts, providing access to practical insights on the patent landscape around the world.

Smart & Biggar is widely recognized as Canada’s leading firm for intellectual property law, with offices in Ottawa, Toronto, Montreal, Vancouver and Calgary. We are leaders in intellectual property and technology law and have been serving clients for over a century.